Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON ACTINIUM PHARMACEUTICALS, INC. (ATNM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is the Investigation About?

On August 5, 2024, before market hours, Actinium issued a press release providing an update on the planned Biologics License Application (“BLA”) filing for its radiotherapy product, Iomab-B, revealing that the FDA had determined that “the analyses from the [Phase 3 “Sierra Trial”] do not adequately support a BLA filing for Iomab-B and requires an additional clinical study.”

On this news, Actinium’s stock price fell $3.69, or 59.8%, to close at $2.48 per share on August 5, 2024, thereby injuring investors.

Contact Us to Participate or Learn More:

If you purchased Actinium securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Century City, California 90067
Call us at: 310-914-5007
Email us at: [e-mail]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.